Securities Class Actions – Page 37 – ClaimsFiler

Case Type: Securities Class Actions

Orphazyme A/S is a biopharmaceutical company that develops therapies for the treatment of neurodegenerative orphan diseases. The Company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Orphazyme conducts its U.S. operations through its whollyowned subsidiary, Orphazyme US, which is focused on U.S. regulatory review and preparing for the Company’s first potential U.S. commercial launch, including legal, commercial, finance, advocacy relations, regulatory, and medical affairs functions. Orphazyme’s lead drug candidate is arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C (“NPC”), Amyotrophic Lateral Sclerosis (“ALS”), and Inclusion Body Myositis (“IBM”).

James River Group Holdings, Ltd. is a Bermuda-based holding company that owns and operates a group of specialty insurance and reinsurance companies. In 2014, James River ramped up its Commercial Auto Division by underwriting a new type of insurance policy that covered Rasier LLC (“Rasier”), a subsidiary of the ride-sharing company Uber Technologies, Inc.

CarLotz, Inc. operates a consignment-to-retail used vehicle marketplace where corporate vehicle sourcing partners and retail sellers of used vehicles can sell at prices that are, on average, below those of traditional dealerships.

Draftkings Inc. operates as a digital sports entertainment and gaming company in the U.S. It operates through two segments, Business-to-Consumer and Business-to-Business. The Company provides users with daily sports, sports betting, and iGaming opportunities. It is also involved in the design, development, and licensing of sports betting and casino gaming platform software for online and retail sportsbook, and casino gaming products. The Company distributes its product offerings through various channels, including traditional websites, direct app downloads, and direct-to-consumer digital platforms.

Rekor Systems, Inc. through its subsidiaries, provides vehicle identification and management systems based on artificial intelligence in the U.S., Canada, and internationally. Rekor was formerly known as “Novume Solutions, Inc.” and traded under the ticker symbol “NVMM” before changing its name to “Rekor Systems, Inc.” and its ticker symbol to “REKR” on April 30, 2019.

Athira Pharma, Inc. describes itself as a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration for those suffering from devastating neurological diseases, including Alzheimer’s disease. The Company’s product candidates aim to provide rapid cognitive improvement and alter the course of neurological diseases with their novel mechanism of action.

Home Point Capital Inc., together with its subsidiaries, operates as a residential mortgage originator and service provider. The Company operates through two segments, Origination and Servicing. The Origination segment sources loans through direct, wholesale, and correspondent channels. The Servicing segment offers collecting loan payments; remitting principal and interest payments to investors; managing escrow funds for the payment of mortgage-related expenses, such as taxes and insurance; and performing loss mitigation activities on behalf of investors and administering mortgage loans. On January 8, 2021, Home Point filed a registration statement on Form S-1 with the SEC in connection with the IPO, which, after amendment, was declared effective on January 28, 2021.

Ocugen, Inc identifies itself as a biopharmaceutical company focused on developing gene therapies to cure blindness and developing a vaccine to save lives from COVID-19. The company’s main developments are a modifier gene therapy platform based on nuclear hormone receptors (“NHRs”) to generate therapies for patient with inherited retinal diseases (“IRDs”) and dry age-related macular degeneration (“AMD”).

Natural-gas producer EQT drills for gas primarily in Pennsylvania, West Virginia and Ohio, utilizing the practice of “fracking” to extract gas from shale deposits.  EQT sought to acquire a rival company, Rice by way of a merger (the “Rice Acquisition” or “Acquisition”). Rice held various tracts of lands adjacent to EQT’s property.  The Rice Acquisition, announced on June 19,  2017,  would  expand  the  total  acreage  available  for  EQT’s  drilling  and  fracking.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of acute pain. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-tosevere acute pain. DSUVIA is a potent opioid painkiller that is of particular use in certain special circumstances where adult patients may not be able to swallow oral medication and where access to intravenous pain relief is not possible.

Nutanix, Inc. purports to be a cloud computing software company headquartered in San Jose, California known for pioneering its “core” hyper-converged infrastructure (“HCI”) software technology, which combines the components of data center computing (server, storage, and virtualization) into a single scalable machine through software.

Nuance Communications, Inc. is a pioneer and a leading provider of conversational AI and cloud-based ambient clinical intelligence for healthcare providers. Nuance’s products include the Dragon Ambient eXperience, Dragon Medical One and PowerScribe One for radiology reporting, all leading clinical speech recognition SaaS offerings built on Microsoft Azure.

GW Pharmaceuticals, PLC is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from their proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. The Company has two primary, more developed products: Epidiolex and Nabiximols (Sativex). GW also has a deep pipeline of additional cannabinoid product candidates and novel compounds, including compounds in Phase 1, Phase 2, and Phase 3 trials.

We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.

OK